Michael A. Swit, Esq., has been tackling critical FDA legal and regulatory issues since 1984. In November 2017, he returned to private law practice after 3 years as Senior Director, Legal, Regulatory, at San Diego-based Illumina, Inc., the world's leading developer of gene sequencing technologies, which he joined in December 2014. His multi-faceted experience includes serving, earlier in his career, for three and a half years as corporate vice president, general counsel and secretary of Par Pharmaceutical, a publicly-traded, generic drug company and, thus, he brings an industry and commercial perspective to his work with FDA-regulated companies. He then served for over four years as CEO of FDAnews.com, a premier publisher of newsletters and other specialty information products for the FDA-regulated community. His private FDA regulatory law practice included service as Special Counsel in the FDA Law Practice Groups of several major law firms, most recently from March 2012 to December 2014, in the San Diego office of Duane Morris LLP. From 2004 to 2011, he was a Vice President at The Weinberg Group, a preeminent FDA regulatory consulting firm. Mr. Swit has lectured and written on a variety of subjects relating to FDA law, regulation and related commercial activities, and is a former member of the Food and Drug Law Journal Editorial Board. He earned his A.B., magna cum laude, with high honors in history, from Bowdoin College and his law degree at Emory University School of Law. Mr. Swit currently is a member of the California bar and inactive in D.C. and Virginia.